Abstract: An IMD may include a housing with a controller and a power supply disposed within the housing. A distal electrode may be supported by a distal electrode support that biases the distal electrode toward an extended position in which the distal electrode extends distally from the distal end of the housing and allows the distal electrode to move proximally relative to the extended position in response to an axial force applied to the distal electrode in the proximal direction. In some cases, the distal electrode support may include a tissue ingrowth inhibiting outer sleeve that extends along the length of the distal electrode support and is configured to shorten when the distal electrode moves proximally relative to the extended position and to lengthen when the distal electrode moves back distally toward the extended position in order to accommodate movement of the distal electrode.

Abstract: Implantable medical devices such as leadless stimulation devices that may provide longer battery life while minimizing device size. In some cases, having the outer housing of the implantable medical device serve multiple roles, such as the battery case for an internal battery, may permit reduced device size by eliminating one or more layers or components within the device.

Abstract: A leadless pacing device may include a housing having a proximal end and a distal end, and a set of one or more electrodes supported by the housing. The housing may include a first a distal extension extending distally from the distal end thereof. One or more electrodes may be supported by the distal extension. The leadless pacing device may be releasably coupled to an expandable anchor mechanism.

Abstract: Implantable medical devices such as leadless cardiac pacemakers may be configured to communicate using more than one mode of communication. For example, in some cases, an implantable medical device may be configured to communicate via conducted communication in some circumstances and to communicate via inductive communication in other circumstances. In some cases, the implantable medical device may be configured to switch between communication modes in order to improve communication.

Abstract: Near-field energy transmitters for charging a rechargeable power source of an implantable medical device (IMD). In some cases, the transmitter may include an output driver that may drive a transmit coil such that near-field energy is transmitted to the IMD at a determined frequency. In some cases, the IMD may include a receiving coil that may capture the near-field energy and then convert the near-field energy into electrical energy that may be used to recharge the rechargeable power source. Since the rechargeable power source does not have to maintain sufficient energy stores in a single charge for the entire expected life of the IMD, the power source itself and thus the IMD may be made smaller while still meeting device longevity requirements.

Abstract: A leadless cardiac pacemaker (LCP) is configured to sense cardiac activity and to pace a patient's heart and is disposable within a ventricle of the patient's heart. The LCP MAY include a housing, a first electrode and a second electrode that are secured relative to the housing and are spaced apart. A controller is disposed within the housing and is operably coupled to the first electrode and the second electrode such that the controller is capable of receiving, via the first electrode and the second electrode, electrical cardiac signals of the heart. The LCP may include a pressure sensor and/or an accelerometer. The controller may determine a pace time within a cardiac cycle based at least in part upon an indication of metabolic demand.

Abstract: A ventricular implantable medical device that is configured to detect an atrial timing fiducial from the ventricle. The ventricular implantable medical is configured to deliver a ventricular pacing therapy to the ventricle based on the detected atrial timing fiducial. If the ventricular implantable medical device temporarily fails to detect atrial activity because of noise, posture, patient activity or for any other reason, an atrial implantable medical device may be configured to communicate atrial events to the ventricular implantable medical device and the ventricular implantable medical device may synchronize the ventricular pacing therapy with the atrium activity based on those communications.

Abstract: Implantable leadless pacing devices and medical device systems including an implantable leadless pacing device are disclosed. An example implantable leadless pacing device may include a pacing capsule. The pacing capsule may include a housing. The housing may have a proximal region and a distal region. A first electrode may be disposed along the distal region. One or more anchoring members may be coupled to the distal region. The anchoring members may each include a region with a compound curve.

Abstract: A system for lead integrity monitoring includes an implantable medical device (IMD) having a housing enclosing a control circuit; and a lead, having a first sensor. The lead is coupled to the housing and electrically coupled to the control circuit. The system also includes at least one processing device configured to identify a first lead failure alert based on a first set of information; obtain a second set of information generated by a second sensor; perform an evaluation of the first set of information in the context of the second set of information; and confirm or cancel the first lead failure alert based on the evaluation.

Abstract: Methods, systems and devices for providing cardiac resynchronization therapy (CRT) to a patient using a leadless cardiac pacemaker (LCP) and an extracardiac device (ED). The LCP is configured to deliver pacing therapy at a pacing interval. Illustratively, the ED may be configured to analyze the cardiac cycle including a portion preceding the pacing therapy delivery for one or several cardiac cycles, and determine whether an interval from the P-wave to the pace therapy in the cardiac cycle(s) is in a desired range. In an example, if the P-wave to pace interval is outside the desired range, the ED communicates to the LCP to adjust the pacing interval.

Abstract: Implantable medical devices (IMD), such as but not limited to leadless cardiac pacemakers (LCP), subcutaneous implantable cardioverter defibrillators (SICD), transvenous implantable cardioverter defibrillators, neuro-stimulators (NS), implantable monitors (IM), may be configured to communicate with each other. In some cases, a first IMD may transmit instructions to a second IMD. In order to improve the chances of a successfully received transmission, the first IMD may transmit the instructions several times during a particular time frame, such as during a single heartbeat. If the second IMD receives the message more than once, the second IMD recognizes that the messages were redundant and acts accordingly.

Abstract: Embodiments of the disclosure include systems and methods for obtaining high-resolution data from implantable medical devices (IMDs) by triggering a limited-time system behavior change. For example, embodiments include utilizing study prescriptions for batching data obtained by an IMD, communicating the batched data to an external device, and reconstructing the batched data at the external device. Study prescriptions refer to sets of instructions, conditions, protocols, and/or the like, that specify one or more of an information gathering scheme and a communication scheme, and may be configured, for example, to obtain information at a resolution sufficient for performing a certain analysis (e.g., associated with a diagnostic model), while managing the resulting impact to device longevity and/or performance.

Abstract: Embodiments herein relate to medical devices and methods for using the same to treat cancerous tumors within a bodily tissue. A medical device system is included having an electric field generating circuit configured to generate one or more electric fields and a control circuit in communication with the electric field generating circuit. The control circuit configured to control delivery of the one or more electric fields from the electric field generating circuit. The system can include two or more electrodes to deliver the electric fields to a site of a cancerous tumor within a patient and a temperature sensor to measure the temperature of tissue at the site of the cancerous tumor. The control circuit can cause the electric field generating circuit to generate one or more electric fields at frequencies selected from a range of between 10 kHz to 1 MHz. Other embodiments are also included herein.

Abstract: Embodiments herein relate to medical devices and methods for using the same to treat cancerous tumors within a bodily tissue. A medical device system is included having at least one electric field generating circuit configured to generate one or more electric fields; control circuitry in communication with the electric field generating circuit, the control circuitry configured to control delivery of the one or more electric fields from the at least one electric field generating circuit; and two or more electrodes to deliver the electric fields to the site of a cancerous tumor within a patient. At least one electrode can be configured to be implanted. At least one electrode can be configured to be external. The control circuitry can cause the electric field generating circuit to generate one or more electric fields at frequencies selected from a range of between 10 kHz to 1 MHz.

Abstract: Embodiments herein relate to medical devices and methods for using the same to treat cancerous tumors within a bodily tissue. A medical device system is included having an electric field generating circuit and control circuitry configured to control delivery of the one or more electric fields from the electric field generating circuit to the site of the cancerous tissue. An implantable lead is included having a lead body including a first electrical conductor disposed within the lead body, and a first electrode coupled to the lead body, the first electrode in electrical communication with the first electrical conductor, wherein the first electrical conductor forms part of an electrical circuit by which the electric fields from the electric field generating circuit are delivered to the site of the cancerous tissue, and the first electrode can include a conductive coil filar disposed around the lead body. Other embodiments are also included herein.

Abstract: Embodiments herein relate to a medical device for treating a cancerous tumor, the medical device having a first lead including a first wire and second wire; a second lead can include a third wire and fourth wire; and a first electrode in electrical communication with the first wire, a second electrode in electrical communication with the second wire, a third electrode in electrical communication with the third wire, and a fourth electrode in electrical communication with the fourth wire. The first and third electrodes form a supply electrode pair configured to deliver one or more electric fields to the cancerous tumor. The second and fourth electrodes form a sensing electrode pair configured to measure an impedance of the cancerous tumor independent of an impedance of the first electrode, the first wire, the third electrode, the third wire, and components in electrical communication therewith. Other embodiments are also included herein.

Abstract: Embodiments herein relate to a method for treating a cancerous tumor located within a subject. The method can include applying one or more electric fields at or near a site of the cancerous tumor, where the cancerous tumor can include a cancerous cell population. The one or more applied electric fields are effective to delay mitosis and cause mitotic synchronization within a proportion of the cancerous cell population. The method can include removing the one or more electric fields to allow mitosis to proceed within the cancerous cell population. The method can include administering a chemotherapeutic agent to the subject after the one or more electric fields have been removed. Other embodiments are also included herein.

Abstract: Embodiments herein relate to a medical device for treating a cancerous tumor, including an electric field generating circuit configured to generate one or more electric fields at or near a site of the cancerous tumor and control circuitry in communication with the electric field generating circuit. The medical device includes one or more supply wires in electrical communication with the electric field generating circuit and one or more supply electrodes. The supply electrodes are configured to deliver an electric field at or near the site of the cancerous tumor. The medical device can include one or more sensing wires in electrical communication with the control circuitry and one or more sensing electrodes. The sensing electrodes can be configured to measure an impedance of the cancerous tumor at at least two different electric field strengths. Other embodiments are also included herein.

Abstract: Systems and methods for monitoring patients with respiratory diseases are described. A system may include a sensor circuit to sense a respiration signal and at least one hemodynamic signal. The system may detect a specified respiratory phase from the respiration signal, and generate from the hemodynamic signal one or more signal metrics that are correlative to at least one of a systolic blood pressure, a blood volume, or a cardiac dimension. The system may detect a restrictive or obstructive respiratory condition when the hemodynamic signal metric indicates hemodynamic deterioration during a specified respiratory phase. The system may additionally classify the detected restrictive or obstructive respiratory condition into one of two or more categories, and deliver a therapy based on the detection or the classification.

Abstract: Methods, systems and devices for providing cardiac resynchronization therapy (CRT) to a patient using a leadless cardiac pacemaker (LCP) and an extracardiac device (ED). The LCP is configured to deliver pacing therapy at a pacing interval. Illustratively, the ED may be configured to analyze the cardiac cycle including a portion preceding the pacing therapy delivery for one or several cardiac cycles, and determine whether an interval from the P-wave to the pace therapy in the cardiac cycle(s) is in a desired range. In an example, if the P-wave to pace interval is outside the desired range, the ED communicates to the LCP to adjust the pacing interval.